Advanced search
Publication Cover
Bioengineered Volume 12, 2021 - Issue 1
Submit an article Journal homepage
3,008
Views
36
CrossRef citations to date
0
Altmetric
Research paper

Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9)

Hanwen Zhanga Department of Orthopaedics, The Affiliated Hospital of Southwest Medical University, Luzhou City, P.R. China
,
Shuya Liub Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou City, P.R. China
,
Lian Tanga Department of Orthopaedics, The Affiliated Hospital of Southwest Medical University, Luzhou City, P.R. China
,
Jianhua Gea Department of Orthopaedics, The Affiliated Hospital of Southwest Medical University, Luzhou City, P.R. China
&
Xiaobo Lua Department of Orthopaedics, The Affiliated Hospital of Southwest Medical University, Luzhou City, P.R. ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1566-7858
ORCID Icon
Pages 162-171 | Received 26 Oct 2020, Accepted 08 Dec 2020, Published online: 28 Dec 2020

References

  • Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.
  • Whelan JS, Davis LE. Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol. 2018;36(2):188–193.
  • Payne D. RNA therapies. Nature. 2019;574(7778):S1.
  • Xu J, Bai J, Zhang X, et al. A comprehensive overview of lncRNA annotation resources. Brief Bioinform. 2017;18(2):236–249.
  • Koch L. Functional genomics: screening for lncRNA function. Nat Rev Genet. 2017;18(2):70.
  • Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA Interactions. Methods Mol Biol. 2016;1402:271–286.
  • Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–352.
  • Chan JJ, Noncoding TY. RNA:RNA regulatory networks in cancer. Int J Mol Sci. 2018;19(5):1310.
  • Mu M, Niu W, Zhang X, et al. LncRNA BCYRN1 inhibits glioma tumorigenesis by competitively binding with miR-619-5p to regulate CUEDC2 expression and the PTEN/AKT/p21 pathway. Oncogene. 2020;39(45):6879–6892.
  • Zheng S, Guo Y, Dai L, et al. Long intergenic noncoding RNA01134 accelerates hepatocellular carcinoma progression by sponging microRNA-4784 and downregulating structure specific recognition protein 1. Bioengineered. 2020;11(1):1016–1026.
  • Chen CW, Fu M, Du ZH, et al. Long noncoding RNA MRPL23-AS1 promoteoid cystic carcinoma lung metastasis. Cancer Res. 2020;80(11):2273–2285.
  • Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463.
  • Ye G, Yang Q, Lei X, et al. Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. Theranostics. 2020;10(17):7545–7560.
  • Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017;1008:1–46.
  • Karreth FA, Pandolfi PP. ceRNA cross-talk in cancer: when ce-bling rivalries go awry. Cancer Discov. 2013;3(10):1113–1121.
  • Zhang Y, Xu Y, Feng L, et al. Comprehensive characterization of lncRNA-mRNA related ceRNA network across 12 major cancers. Oncotarget. 2016;7(39):64148–64167.
  • Noh JH, Kim KM, McClusky WG, et al. Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA. 2018;9(3):e1471.
  • Liao WT, Ye YP, Zhang NJ, et al. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol. 2014;232(4):415–427.
  • Zhu ED, Li N, Li BS, et al. miR-30b, down-regulated in gastric cancer, promotes apoptosis and suppresses tumor growth by targeting plasminogen activator inhibitor-1. Plos One. 2014;9(8):e106049.
  • Xu C, He Z, Lin C, et al. MiR-30b-5p inhibits proliferation and promotes apoptosis of medulloblastoma cells via targeting MYB proto-oncogene like 2 (MYBL2). J Investig Med. 2020;68(6):1179–1185.
  • Gao D, Zhou Z, Huang H. miR-30b-3p inhibits proliferation and invasion of hepatocellular carcinoma cells via suppressing PI3K/Akt pathway. Front Genet. 2019;10:1274.
  • Xu J, Lv H, Zhang B, et al. miR-30b-5p acts as a tumor suppressor microRNA in esophageal squamous cell carcinoma. J Thorac Dis. 2019;11(7):3015–3029.
  • Xu Y, Yao T, Huang K, et al. Circular RNA circTUBGCP3 is up-regulated and promotes cell proliferation, migration and survivability via sponge mir-30b in osteosarcoma. Onco Targets Ther. 2020;13:3729–3737.
  • Pecci A, Ma X, Savoia A, et al. MYH9: structure, functions and role of non-muscle myosin IIA in human disease. Gene. 2018;664(152–67):152–167.
  • Lin X, Li AM, Li YH, et al. Silencing MYH9 blocks HBx-induced GSK3beta ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):13.
  • Liu L, Ning Y, Yi J, et al. miR-6089/MYH9/beta-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression. Biomed Pharmacother. 2020;125:109865.
  • Zhou P, Li Y, Li B, et al. NMIIA promotes tumor growth and metastasis by activating the Wnt/beta-catenin signaling pathway and EMT in pancreatic cancer. Oncogene. 2019;38(27):5500–5515.
  • Zhou W, Fan MY, Wei YX, et al. The expression of MYH9 in osteosarcoma and its effect on the migration and invasion abilities of tumor cell. Asian Pac J Trop Med. 2016;9(6):597–600.
  • Wang Y, Liu S, Zhang Y, et al. Myosin heavy chain 9: oncogene or tumor suppressor gene? Med Sci Monit. 2019;25:888–892.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.